Early Risk Assessment of Type 2 Diabetes Mellitus Through the Use of the Biomarker Adiponectin

The prevalence of diabetes is steadily increasing, most markedly in middle-income countries. Early risk assessment is vital not only because of health implications, but also because it brings about economic loss to people with diabetes.

The Randox automated immunoturbidimetric adiponectin test offers an improved method for assessing type 2 diabetes mellitus (T2DM) risk, in a convenient format for clinical use.